Market Overview
Size, demand pool, and mix
- Brevintel analysis values the joint pain injections market at USD 6.1 billion in 2025 ($6.1B), or USD 6,081.36 million, after approximately USD 5.1 billion in 2022 and USD 5.7 billion in 2024.
- The outlook reaches USD 12.8 billion by 2035 ($12.8B), or USD 12,753.58 million, with a 7.8% narrative CAGR while source cards list 8.4%.
- Near-term sizing also cites about USD 6.5 billion in 2026 as the first year of the 2026–2035 window.
- Pfizer led with over 23.5% share in 2025; Pfizer, Sanofi, Zimmer Biomet, Bioventus, and Ferring collectively held 56.2%.
- Musculoskeletal conditions affect an estimated 1.71 billion people globally and remain a leading source of disability.
- Industry data cite 528 million people living with osteoarthritis in 2019, with the knee the most commonly affected site.
- A 2025 analysis estimated approximately 607 million prevalent osteoarthritis cases in 2021.
- High-BMI-attributable osteoarthritis disability-adjusted life years rose from 1.45 million in 1990 to 4.42 million in 2021.
Value mix versus prevalence
- Hyaluronic acid remains the revenue anchor because reimbursement infrastructure and the installed prescriber base are deepest in this modality.
- Platelet-rich plasma, with an approved 8.4% CAGR, has faster growth potential if protocols and payer confidence become more consistent.
- Value creation will not track osteoarthritis prevalence linearly; the commercial question is how much demand migrates from low-cost corticosteroids toward differentiated HA, PRP, and regenerative formats.
- Two parallel markets persist: a reimbursed, protocol-driven HA and corticosteroid channel, and a more fragmented PRP market where providers carry pricing and education.
- Product innovation must fit coding, evidence, and site-of-care workflows, or adoption stays limited even when clinical interest is high.
- U.S. and European regulatory tightening raises development and documentation costs, but can also reduce the ability of lightly resourced suppliers to compete on price alone.
- Established suppliers with robust quality systems are positioned to benefit from premiumization and procedural migration rather than undifferentiated unit expansion.
- The strongest upside sits in single-injection HA, extended-release corticosteroids, standardized PRP systems, and combination or regenerative therapies.
Market Dynamics
Demand drivers
- A 2023 assessment of 1990–2020 burden data projected a 74.9% increase in global knee osteoarthritis burden through 2050, creating a long-duration procedure base.
- Epidemiological expansion is assigned a +3.0% CAGR impact, reflecting population aging and accumulated disease rather than a short-cycle purchasing decision.
- Rising obesity increases mechanical loading and inflammation-related risk while broadening incidence beyond the oldest age groups.
- Injections occupy a clinically useful position between conservative management and arthroplasty for patients delaying surgery or maintaining mobility.
- Single-injection HA and extended-release corticosteroids are especially attractive when repeat visits are a barrier to completing a treatment course.
- Ultrasound-guided procedures support use in anatomically difficult joints, though they also raise the importance of clinician capability and equipment availability.
- A U.S. National Poll on Healthy Aging found that approximately 70% of adults aged 50 to 80 reported joint pain, highlighting a large pool that may seek intervention.
- JOYCLU's 2021 Japanese commercialization shows that novel HA-based chemistry can reach market when clinical proposition and regulatory positioning are clear.
Constraints and access
- Clinical evidence is not equally consistent across modalities, disease stages, and protocols, so broad category claims are less persuasive than evidence tied to severity and dosing.
- HA remains subject to divergent guideline positions, including 2024 EUROVISCO consensus guidance on viscosupplementation in knee osteoarthritis.
- Corticosteroids have a well-established short-term role, but repeated administration must be managed carefully, limiting revenue expansion through frequent repeats.
- PRP preparation and administration variability makes it difficult to translate favorable trials into uniform real-world outcomes.
- U.S. discussion of HA classification and the implementation burden associated with EU MDR show why regulatory strategy cannot be separated from commercial strategy.
- For large companies, compliance investment can create a defensible position; for smaller suppliers, it can delay launches or force distributor dependence.
- Awareness expands demand only when patients can progress from recognizing chronic joint pain to specialist evaluation and a viable payment pathway.
- Geographic expansion is most meaningful where specialist capacity and reimbursement improve together, especially in Asia Pacific, Latin America, and the Middle East.
Segmentation Analysis
Injection type
- HA injections account for 64.90% of global revenue in 2025, equivalent to approximately USD 3,946.80 million, spanning five-, three-, and single-injection regimens.
- Single-injection HA reduces repeat-appointment burden; Ferring's EUFLEXXA is a non-avian formulation, while Anika, Bioventus, Sanofi, OrthogenRx, and Zimmer Biomet compete on regimen length.
- Corticosteroid injections represent 22.50% of 2025 revenue, or approximately USD 1,368.31 million, supported by low relative cost, rapid onset, and established reimbursement.
- Pfizer's Depo-Medrol remains a major corticosteroid product, while ZILRETTA provides an extended-release alternative for osteoarthritis knee pain.
- PRP accounts for 9.10% of market revenue, or approximately USD 553.40 million, in 2025 and is projected to grow at an 8.4% CAGR.
- Arthrex, EmCyte Corporation, and Stryker participate through PRP and orthobiologic processing platforms that must fit clinic and ASC workflows.
- Other injection types account for 3.50% of revenue, or approximately USD 212.85 million, in 2025, including HA-drug conjugates, combinations, and emerging cell-based approaches.
- JOYCLU combines HA with an anti-inflammatory agent, while Ciplostem introduces an allogeneic cell-therapy proposition for selected knee osteoarthritis patients.
Joint type
- The knee segment accounts for 74.14% of revenue, or approximately USD 4,508.72 million, in 2025 and is projected to reach approximately USD 9.6 billion by 2035.
- This concentration reflects knee osteoarthritis prevalence, products specifically indicated for the knee, and comparatively established technique and reimbursement pathways.
- The knee is the primary evidence-development arena for HA, corticosteroid, PRP, and emerging regenerative therapies.
- Shoulder and elbow applications represent 16.77% of revenue, or approximately USD 1,019.84 million, and are expected to grow at a 7.4% CAGR.
- These applications mix osteoarthritis, soft-tissue, tendon-related, and sports-medicine indications, with greater weight on imaging and specialist skill.
- Ankle and hip applications account for 5.93% of revenue, or approximately USD 360.62 million, in 2025; hip injections frequently require image guidance because of joint depth.
- Ankle injection demand includes post-traumatic osteoarthritis and sports-medicine care and is more specialist-led than high-volume knee protocols.
- Other joint types account for 3.16% of revenue, or approximately USD 192.17 million, in 2025, including small joints and other specialized pain-management applications.
End use
- Hospitals account for 56.55% of 2025 revenue, or approximately USD 3,439.01 million, reflecting integrated imaging, orthopedic consultation, rheumatology, and buy-and-bill HA models.
- The hospital channel favors suppliers that can meet formulary, purchasing, documentation, and supply-reliability requirements at scale.
- Orthopedic and pain clinics account for 26.70% of revenue, or approximately USD 1,623.72 million, and are projected to expand at an 8.2% CAGR.
- Clinics are particularly important for PRP because they can integrate patient-paid treatment, blood processing, imaging, and follow-up in one practice.
- OrthogenRx's direct-purchase approach for GenVisc 850 and TriVisc illustrates how suppliers can serve clinics seeking alternatives to complex reimbursement administration.
- ASCs account for 9.80% of market revenue, or approximately USD 595.97 million, in 2025, as appropriate orthopedic procedures move into lower-cost outpatient settings.
- Single-dose products and streamlined PRP systems are especially compatible with ASC workflow because they minimize storage, preparation, and repeat-visit requirements.
- Other end users account for 6.95% of market revenue, or approximately USD 422.65 million, in 2025, including specialized outpatient, rehabilitation, and research settings.
Regional Outlook
North America and Europe
- North America accounts for 47.08% of global market revenue in 2025, or approximately USD 2,863.10 million, and is expected to remain the largest regional pool through 2035.
- The United States contributes approximately USD 2.6 billion, supported by a large osteoarthritis population, specialist infrastructure, and Medicare-linked reimbursement for eligible HA procedures.
- Reimbursement methodology, local coverage decisions, and payer formulary contracts can shift product economics quickly even when patient demand remains intact.
- Bioventus' Aetna Medicare Advantage agreement for DUROLANE illustrates access strategy, while a 2022 reimbursement change shows the risk of relying on a single payment framework.
- Canada supports stable demand but typically has more constrained provincial funding and slower access to premium injection formats.
- Europe represents approximately USD 1.5 billion of market revenue in 2025, supported by aging populations and established orthopedic care.
- EU MDR imposes a common regulatory framework, while payment decisions remain substantially national or regional.
- Germany, France, the United Kingdom, Italy, and Spain remain the largest European opportunities, but their access conditions are not interchangeable.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific is projected to be the fastest-growing region, at an 8.3% CAGR, with China and India offering the largest long-term patient pools.
- Japan is the region's most developed market for approved injectable therapies and rewards clinical and regulatory rigor.
- India's Ciplostem launch and Japan's JOYCLU commercialization demonstrate that Asia Pacific can originate products, not merely import HA and PRP systems.
- Australia and South Korea offer mature specialist markets where differentiated products can gain access through approval and provider adoption.
- Latin America is expanding from a comparatively smaller base, led by Brazil, where private orthopedic care sits alongside public demand for affordable musculoskeletal management.
- Bioventus selected Pfizer as its exclusive DUROLANE distribution partner in Brazil, underscoring the importance of established local commercialization capability.
- Mexico and Argentina are secondary opportunities, but purchasing power and reimbursement limitations require portfolios that span premium and accessible options.
- Gulf markets can support premium HA and selected PRP procedures; Saudi Arabia's 2024 authorization of MBI's ArtiAid and ArtiAidPlus illustrates ongoing regulatory activity, with practical focus also on the United Arab Emirates and South Africa.
Competitive Landscape
Structure
- The five leading suppliers — Zimmer Biomet, Ferring, Pfizer, Sanofi, and Bioventus — collectively account for approximately 56.2% of global market revenue.
- Pfizer represents approximately 23.5% through its corticosteroid franchise, while HA, PRP, and regenerative developers compete on different commercial bases.
- Anika Therapeutics markets HA products including Monovisc and Orthovisc and is developing Cingal, an HA-triamcinolone hexacetonide combination.
- Anika reported USD 26.2 million in first-quarter 2025 revenue from continuing operations and described progress in its Cingal and Hyalofast development programs.
- Arthrex participates in orthobiologics through its autologous conditioned plasma and Angel PRP systems, integrated with orthopedic and sports-medicine physician networks.
- Bioventus offers a one-, three-, and five-injection HA portfolio through DUROLANE, Gelsyn-3, and Supartz FX; 2023 results showed pain-treatment volume growth amid Medicare reimbursement changes.
- Cipla entered the advanced joint-injection category with Ciplostem, launched in India in December 2025 with Stempeutics Research.
- Ciplostem combines 25 million bone-marrow-derived mesenchymal stromal cells with HA for Grade II/III knee osteoarthritis, while EmCyte supplies point-of-care PRP and bone-marrow-concentrate systems.
Integrated producers
- Pfizer
- Sanofi
- Zimmer Biomet
- Stryker
Specialty suppliers
- Bioventus
- Ferring
- Anika Therapeutics
- Arthrex
- EmCyte Corporation
- Cipla
- OrthogenRx
- Ono Pharmaceutical